Expression of the B-cell receptor subunit CD79a on MDSCs induced by metastatic tumors.

<p>CD79a/b expression on the Ly6C⁺ myeloid cell population in multiple tumor models was assessed by flow cytometry. (A) Expression of the B-cell markers CD19 and CD79a/b on splenocytes from naïve and 67NR and 4T1 tumor-bearing mice. (B) Ly6C and CD79a/b expression on viable leukocytes from lungs and spleens of Balb/c mice bearing 67NR or 4T1 tumors at day 28 post-inoculation. The box indicates the immature myeloid population. CD79 on myeloid cells is recognized by the CD79-11 but not the CD79-12 antibody. (C) CD79a expression on MDSCs was also evaluated in the Lewis Lung Carcinoma transplantable metastatic lung cancer model (C57Bl/6 background). (D,E) Similar evaluation was done in two genetically-engineered models of breast cancer; the metastatic MMTV-PyMT model (D) on the FVB/N background (age 3 months) and the non-metastatic Brca1 model (E) on a mixed genetic background (age 6 months).